We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
Pacific Biosciences of California (PACB - Free Report) closed at $1.33 in the latest trading session, marking a -5% move from the prior day. This move lagged the S&P 500's daily loss of 1.51%. Elsewhere, the Dow saw a downswing of 0.97%, while the tech-heavy Nasdaq depreciated by 2.01%.
The stock of maker of genetic analysis technology has fallen by 16.67% in the past month, lagging the Medical sector's loss of 7.54% and the S&P 500's loss of 3.63%.
The investment community will be closely monitoring the performance of Pacific Biosciences of California in its forthcoming earnings report. On that day, Pacific Biosciences of California is projected to report earnings of -$0.17 per share, which would represent a year-over-year decline of 13.33%. At the same time, our most recent consensus estimate is projecting a revenue of $41 million, reflecting a 10.36% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.54 per share and a revenue of $175.4 million, demonstrating changes of -1.89% and +9.62%, respectively, from the preceding year.
Investors should also pay attention to any latest changes in analyst estimates for Pacific Biosciences of California. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Pacific Biosciences of California is currently sporting a Zacks Rank of #2 (Buy).
The Medical - Instruments industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Pacific Biosciences of California (PACB - Free Report) closed at $1.33 in the latest trading session, marking a -5% move from the prior day. This move lagged the S&P 500's daily loss of 1.51%. Elsewhere, the Dow saw a downswing of 0.97%, while the tech-heavy Nasdaq depreciated by 2.01%.
The stock of maker of genetic analysis technology has fallen by 16.67% in the past month, lagging the Medical sector's loss of 7.54% and the S&P 500's loss of 3.63%.
The investment community will be closely monitoring the performance of Pacific Biosciences of California in its forthcoming earnings report. On that day, Pacific Biosciences of California is projected to report earnings of -$0.17 per share, which would represent a year-over-year decline of 13.33%. At the same time, our most recent consensus estimate is projecting a revenue of $41 million, reflecting a 10.36% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.54 per share and a revenue of $175.4 million, demonstrating changes of -1.89% and +9.62%, respectively, from the preceding year.
Investors should also pay attention to any latest changes in analyst estimates for Pacific Biosciences of California. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Pacific Biosciences of California is currently sporting a Zacks Rank of #2 (Buy).
The Medical - Instruments industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.